Peter W. PENG, Author at MediaMedic

CSCO 2024: Dr. Jun Zhu Spearheads China’s Breakthroughs in Anti-Tumor Drug Development

By Peter W. PENG 2024.10.24

From September 25 to 29, 2024, the 27th Annual Meeting of the Chinese Society of Clinical Oncology (CSCO) was successfully held in Xiamen. Themed Patient-Centered, Sharing the Future, the conference brought together major research advancements and developments from both domestic and international spheres. Over the past two decades, CSCO has been a continuous leader in the development of clinical oncology in China, with numerous experts and scholars contributing to and benefiting from CSCO’s growth. In response to CSCO's initiative, Hematology Frontier established the Growing with CSCO column to look back at the history of this organization alongside Chinese scholars. This issue features an exclusive interview with Dr. Jun Zhu, Vice President of the CSCO Council and Professor at Peking University Cancer Hospital, where he shares his journey of growing with CSCO and highlights the progress and achievements in the field of lymphoma in China.

Neo-AEGIS Study Unveils: Peroperative Chemo Stands Tall in Esophageal Cancer Treatment, Signaling a Customized Future

By Peter W. PENG 2024.10.23

Neo-AEGIS Study Unveils: Peroperative Chemo Stands Tall in Esophageal Cancer Treatment, Signaling a Customized Future Editor's Note: From September 22nd to 24th, 2024, the 20th International Esophageal Cancer Conference (ISDE) took place in Edinburgh, Scotland. The Neo-AEGIS study, which compared the efficacy of perioperative chemotherapy with the CROSS regimen (preoperative chemotherapy combined with radiotherapy) in the treatment of esophageal cancer, captured global attention. As the corresponding author of the study, Dr. John Reynolds from St. James's Hospital in Ireland provided an in-depth interpretation of the research findings and discussed their profound impact on future strategies for esophageal cancer treatment.

CSCO 2024 Visionary: Dr. Jun Zhou Illuminates the Path Forward for Biliary Tract Cancer Treatment

By Peter W. PENG 2024.10.22

From September 25 to 29, 2024, the highly anticipated 27th National Clinical Oncology Conference and CSCO Annual Meeting was successfully held in Xiamen. This prestigious event brought together top experts in the field of oncology from across China, focusing on standardized pathways for diagnosis and treatment of malignant tumors and exploring the latest frontiers. During the conference, Dr. Jun Zhou from Peking University Cancer Hospital delivered a presentation titled “Advances in the Application of New Anticancer Drugs in Biliary Tract Cancer” at the dedicated session on targeted therapy for cholangiocarcinoma. Oncology Frontier had the opportunity to conduct an in-depth interview with Professor Zhou, delving into the current progress in drug treatments for biliary tract cancers and exploring future research directions.

CUA 2024 | Dr. Jeremy Teoh: Addressing Unmet Needs in NMIBC and Exploring Advanced Diagnostic and Treatment Strategies

By Peter W. PENG 2024.10.21

Bladder cancer is one of the most common malignant tumors among the Chinese population, with 75% of cases classified as non-muscle invasive bladder cancer (NMIBC), which has a high postoperative recurrence rate. What are the unmet diagnostic and treatment needs of NMIBC patients? Which research findings may change future clinical practice for NMIBC? During the recent CUA Annual Meeting, Urology Frontier invited Dr. Jeremy Teoh from The Chinese University of Hong Kong to discuss the current unmet needs in NMIBC, the factors influencing recurrence, and the latest research developments that could potentially change clinical practice.

Metabolic-Related Diseases in Autoimmune Hepatitis Patients Promote Liver Fibrosis

By Peter W. PENG 2024.10.21

Introduction: Autoimmune hepatitis (AIH) is a chronic liver disease that affects both men and women, with about 30% of AIH cases occurring in individuals over 60 years old. Metabolic syndrome,…

WCLC 2024丨Furmonertinib Blazes New Trail in EGFR PACC NSCLC: A Quantum Leap in Precision Oncology

By Peter W. PENG 2024.10.18

EGFR P-loop-aC helix compression (PACC) mutation is a recently identified subtype of EGFR mutations in non-small cell lung cancer (NSCLC), and its potential for precision therapy had not been clinically validated until now. At the 2024 World Conference on Lung Cancer (WCLC 2024), during the Presidential Symposium Presentation, the global phase Ib FURTHER trial's proof-of-concept results were revealed. Furmonertinib as monotherapy in first-line treatment of NSCLC patients with EGFR PACC mutations demonstrated outstanding efficacy and safety. Oncology Frontier interviews the study’s principal investigator, Dr. Xiuning Le from the MD Anderson Cancer Center, to delve into how EGFR PACC mutations moved from concept to clinic and how Furmonertinib is pioneering targeted therapy for this subtype of lung cancer.

New Characteristics of BL/BLI Compounds Targeting Non-KPC Enterobacterales

By Peter W. PENG 2024.10.16

Editor's Note: As carbapenem-resistant Gram-negative bacteria (CRO) have become increasingly prevalent, the development and application of novel β-lactam/β-lactamase inhibitor (BL/BLI) combinations have gained significant attention from researchers worldwide. A recent…

Advancing Treatment in #TripleNegativeBreastCancer : Insights from the Keynote 522 Trial

By Peter W. PENG 2024.10.14

We are pleased to share an expert discussion with Dr. Peter Schmid on the findings from the pivotal Keynote 522 trial. This landmark Phase 3 study investigates the impact of combining chemotherapy with immunotherapy (Pembrolizumab) in early-stage triple-negative breast cancer (TNBC). The trial’s results highlight a 34% reduction in the risk of death, marking a significant advancement in patient outcomes and offering new hope for TNBC treatment strategies.

ESMO 2024 丨 Dr. Trevor Leong: The TOPGEAR study confirms that preoperative radiotherapy cannot prolong long-term survival in resectable gastric cancer

By Peter W. PENG 2024.10.14

In the past, there has been ongoing debate about the therapeutic value of radiotherapy in resectable gastric cancer. The TOPGEAR study presented at the 2024 European Society for Medical Oncology (ESMO) Congress (September 13-17, Barcelona) evaluated the comparison between preoperative chemoradiotherapy and perioperative chemotherapy alone. Dr. Trevor Leong, the Principal Investigator from the University of Melbourne in Australia, was interviewed by us on site.

ESMO 2024丨Dr. Junyuan Qi: Cutting Through the Fog, Promising Phase I Results for the New BCL-2 Inhibitor in R/R NHL and AML

By Peter W. PENG 2024.10.13

From September 13th to 17th, the 2024 European Society for Medical Oncology (ESMO) Annual Meeting was held in Barcelona, Spain. As one of the world's top oncology conferences, it brought together experts and scholars from across the globe to share cutting-edge research findings and discuss future directions. At the session dedicated to hematologic malignancies, Dr. Junyuan Qi from the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, presented the first-in-human study of the BCL-2 inhibitor TQB3909 in relapsed or refractory (R/R) non-Hodgkin lymphoma (NHL) and acute myeloid leukemia (AML), showing promising results. Hematology Frontier invited Professor Qi to provide an in-depth analysis of the study and discuss the future clinical applications and research directions for this novel BCL-2 inhibitor.